Hjem › Blodsygdomme
Blodsygdomme kliniske forsøg rekrutterer i USA
34 studier for Blodsygdomme rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Atlanta, GA10 studier
- Boston, MA10 studier
- Houston, TX9 studier
- Los Angeles, CA9 studier
- The Bronx, NY8 studier
- New York City, NY7 studier
- Nashville, TN7 studier
- Mountain View, CA6 studier
- Durham, NC5 studier
- Greenville, NC5 studier
- Portland, OR5 studier
- Washington, DC5 studier
- Seattle, WA5 studier
- Birmingham, AL4 studier
- Milwaukee, WI4 studier
- Philadelphia, PA4 studier
- San Diego, CA4 studier
- Tampa, FL4 studier
- Baltimore, MD3 studier
- Buffalo, NY3 studier
- Columbus, OH3 studier
- Baldwin Park, CA3 studier
- Louisville, KY3 studier
- Kansas City, MO3 studier
- Cleveland, OH3 studier
- Indianapolis, IN3 studier
- Norfolk, VA3 studier
- Cedar Rapids, IA3 studier
- Miami, FL3 studier
- Phoenix, AZ3 studier
- Clifton, NJ3 studier
Efter delstat
- Alabama5 studier
- Arizona3 studier
- Arkansas3 studier
- Californien16 studier
- District of Columbia4 studier
- Florida9 studier
- Georgia11 studier
- Indiana3 studier
- Iowa3 studier
- Kentucky4 studier
- Maryland5 studier
- Massachusetts10 studier
- Minnesota3 studier
- Missouri4 studier
- New Jersey5 studier
- New York12 studier
- North Carolina9 studier
- Ohio6 studier
- Oregon5 studier
- Pennsylvania4 studier
- Tennessee7 studier
- Texas10 studier
- Virginia5 studier
- Washington6 studier
- Wisconsin5 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults
RekruttererFase 1
3 Months – 25 Years · Alle køn · Opdateret 2. okt. 2026 · NCT04806347A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RekruttererFase 3
Alder 12 til 100 · Alle køn · Opdateret 28. sep. 2026 · NCT06439082Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06910969Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RekruttererFase 3
Alder 18 til 71 · Alle køn · Opdateret 23. sep. 2026 · NCT07504458Treatment of Hemophilia A Patients With FVIII Inhibitors
RekruttererObservationsstudie
Alle aldre · Mænd · Opdateret 23. sep. 2026 · NCT04023019A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT06722235(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT04996875A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
RekruttererFase 3
Alder 18 til 70 · Alle køn · Opdateret 11. sep. 2026 · NCT07059000A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06948318Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
RekruttererFase 1/2Frivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 1. sep. 2026 · NCT07601425A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07075185A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT05254743ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 17. aug. 2026 · NCT04398628Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 7. jul. 2026 · NCT07216443Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
Rekrutterer
Op til 55 år · Alle køn · Opdateret 6. jul. 2026 · NCT01666080Therapeutic RSK1 Targeting in Myelofibrosis
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. maj 2026 · NCT07379125A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 30. apr. 2026 · NCT04256317ATHNdataset Registry
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 21. apr. 2026 · NCT06820515Diamond Blackfan Anemia Registry (DBAR)
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 16. apr. 2026 · NCT00106015Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
RekruttererFase 2
Alder 18 til 80 · Alle køn · Opdateret 16. apr. 2026 · NCT06828796Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 19 og opefter · Alle køn · Opdateret 2. apr. 2026 · NCT03207854Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RekruttererFase 3
Alder 12 til 35 · Alle køn · Opdateret 23. mar. 2026 · NCT05477563Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
RekruttererFase 1
1 Month – 45 Years · Alle køn · Opdateret 8. jan. 2026 · NCT04640987Hematology Biobank: In Vitro Study of Blood Disorders
RekruttererObservationsstudie
Alder 12 og opefter · Alle køn · Opdateret 6. jan. 2026 · NCT02442011CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
RekruttererFase 1
3 Months – 30 Years · Alle køn · Opdateret 28. nov. 2025 · NCT06559189Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.